Investigating a new RNA therapy to reduce bleeding by controlling fibrinolysis
Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy
This study is looking at how a process that breaks down blood clots can lead to too much bleeding in people with bleeding disorders, and it aims to help these patients by using special RNA treatments that could make bleeding easier to manage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-10907802 on NIH RePORTER |
What this research studies
This research focuses on understanding how fibrinolysis, the process that breaks down blood clots, contributes to excessive bleeding in patients with bleeding disorders. The team hypothesizes that by using long-acting RNA therapies that target plasminogen, they can effectively reduce fibrinolysis and improve bleeding management. The approach involves delivering these RNA agents through lipid nanoparticles, which are already approved for clinical use. This innovative method aims to provide a long-term solution for patients suffering from various bleeding disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with diagnosed or undiagnosed bleeding disorders who experience acute bleeding episodes.
Not a fit: Patients who do not have bleeding disorders or those whose bleeding is not related to fibrinolysis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective long-term treatments for patients with bleeding disorders, reducing the incidence and severity of bleeding episodes.
How similar studies have performed: While the approach of using RNA therapies is innovative, similar strategies targeting coagulation processes have shown promise in other studies, indicating potential for success.
Where this research is happening
Milwaukee, United States
- Versiti Wisconsin, INC. — Milwaukee, United States (Active)
Researchers
- Principal investigator: Kastrup, Christian — Versiti Wisconsin, INC.
- Study coordinator: Kastrup, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.